Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 6/20 | 0.71 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6290699 | 1.00 | OPRK1 (0.71) | OPRK1OPRD1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6290697 | 1.00 | OPRK1 (0.71) | OPRK1OPRD1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6288110 | 0.83 | OPRK1 (1.00) | OPRK1OPRD1OPRM1 | |
| SCHEMBL6288108 | 0.83 | OPRK1 (1.00) | OPRK1OPRD1OPRM1 | |
| SCHEMBL6288109 | 0.83 | OPRK1 (1.00) | OPRK1OPRD1OPRM1 | |
| SCHEMBL21383340 | 0.83 | SLC6A4 (0.54) | OPRK1OPRD1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6288029 | 0.81 | SIGMAR1 (0.60) | OPRK1OPRD1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL11086789 | 0.81 | SLC6A4 (0.62) | OPRK1OPRD1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL11249000 | 0.78 | SLC6A4 (0.79) | OPRK1OPRD1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL11248997 | 0.78 | SLC6A4 (0.79) | OPRK1OPRD1SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900228-B1 | Opiate compounds, methods of making and methods of use | RESEARCH TRIANGLE INSTITUTE (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1512683-A1 | Novel opiate compounds, methods of making and methods of use | RESEARCH TRIANGLE INSTITUTE (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040146518-A1 | Novel opiate compounds, methods of making and methods of use | RESEARCH TRIANGLE INSTITUTE (US) | 2004-07-29 | — | — | US | disclosed |
| US-20030158415-A1 | Novel opiate compounds, methods of making and methods of use | RESEARCH TRIANGLE INSTITUTE | 2003-08-21 | — | — | US | disclosed |
| US-6593348-B2 | N-substituted(+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine compounds; opiod receptors | RESEARCH TRIANGLE INSTITUTE | 2003-07-15 | — | — | US | disclosed |
| US-6552032-B2 | N-substituted (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl) piperidine (4a) derivatives | RESEARCH TRIANGLE INSTITUTE | 2003-04-22 | — | — | US | disclosed |
| US-6531481-B2 | Opioid receptor antagonists and agonists; for example, a 1-(arylcarbonylaminoalkyl),3,4-dimethyl-4-(3-hydroxyphenyl)-piperidine compound of given formula | RESEARCH TRIANGLE INSTITUTE | 2003-03-11 | — | — | US | disclosed |
| US-20020193602-A1 | Novel opiate compounds, methods of making and methods of use | RESEARCH TRIANGLE INSTITUTE (US) | 2002-12-19 | — | — | US | disclosed |
| US-20020169324-A1 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | RESEARCH TRIANGLE INSTITUTE (US) | 2002-11-14 | — | — | US | disclosed |
| US-20020165396-A1 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | RESEARCH TRIANGLE INSTITUTE (US) | 2002-11-07 | — | — | US | disclosed |
| EP-1061919-A4 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | RES TRIANGLE INST (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-1061919-A1 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | Carrol, Frank Ivy (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999045925-A1 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | RESEARCH TRIANGLE INSTITUTE (US) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169324-A1 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | OPRK1, OPRM1, OPRL1 | OPRK1 1/4885OPRD1 5/4885SLC6A4 189/4885 |
| US-20030158415-A1 | Novel opiate compounds, methods of making and methods of use | OPRL1, OPRM1, OPRK1 | OPRK1 3/4885OPRD1 5/4885SLC6A4 127/4885 |
| US-20020193602-A1 | Novel opiate compounds, methods of making and methods of use | OPRK1, OPRM1, OPRL1 | OPRK1 1/4885OPRD1 5/4885SLC6A4 189/4885 |
| US-20020165396-A1 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | OPRK1, OPRM1, OPRL1 | OPRK1 1/4885OPRD1 5/4885SLC6A4 189/4885 |
| US-20040146518-A1 | Novel opiate compounds, methods of making and methods of use | OPRK1, OPRM1, OPRL1 | OPRK1 1/4885OPRD1 5/4885SLC6A4 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.